Molecular Testing in Gastric Cancer

HER2, PD-L1, CLDN18.2, and MSI/MMR — timed mainly to advanced therapy, with MSI relevant earlier too.

Advanced gastric/GEJ adenocarcinoma commonly needs HER2, PD-L1 (CPS), and CLDN18.2 testing to choose targeted and immunotherapy combinations. MSI/MMR status can influence care even before classic metastatic lines in selected discussions. Testing volume should match decision points so tissue is not exhausted on low-yield panels. Order tests that answer a stage-specific question rather than collecting unused data. Write down your top three questions before the appointment.

Gastric — educational figure — Gastric · educational illustration

Who may be a candidate?

People evaluating molecular testing in gastric cancer within molecular testing in cancer
International patients preparing a structured second-opinion visit
Patients comparing observation, medical care, and procedural options

Possible advantages

Explains how molecular testing in gastric cancer fits into the molecular testing in cancer care pathway
Supports informed consent with alternatives and recovery themes
Highlights red flags that should trigger urgent contact

Limits & realistic expectations

Cannot replace examination, imaging, or pathology
Local protocols and tumor-board decisions may refine timing
Outcomes vary with anatomy, stage, and comorbidity

Step-by-step overview

1
Define the clinical question
Confirm why molecular testing in gastric cancer is being discussed now — diagnosis, staging, treatment, or surveillance.
2
Gather records
Collect imaging, endoscopy, pathology, and prior operative notes before decisions lock.
3
Risk-stratify
Match urgency to red flags, labs, and imaging rather than labels alone.
4
Choose a pathway
Compare observation, medical therapy, endoscopy, and surgery with expected recovery.
5
Plan follow-up
Agree on review timing, warning symptoms, and who to call after hours.

Key points

How molecular testing in gastric cancer fits the pathway
Tap for details
In molecular testing in cancer, “Molecular Testing in Gastric Cancer” is a decision node inside a longer journey: symptoms, confirmation, risk stratification, treatment choice, and follow-up. Reading this chapter alongside the hub overview helps you ask better questions in clinic.
What clinicians weigh
Tap for details
Biomarker tests answer stage-specific treatment or hereditary questions — they are not generic good/bad labels. Your age, comorbidities, prior operations, imaging quality, pathology details, and personal goals can reasonably change the sequence even when the label is the same.
- Disease extent and urgency
- Fitness for anesthesia or procedure
- Alternatives and expected recovery
- Follow-up intensity you can complete
Warning signs worth urgent review
Tap for details · key note inside
Severe progressive pain, fever with rigidity, vomiting with obstipation, heavy bleeding, sudden breathlessness, or a rapidly worsening wound/stoma problem should not wait for a routine slot. When in doubt, seek urgent assessment and bring prior reports.
- Severe progressive pain
- Fever with peritoneal signs
- Vomiting with inability to pass stool/gas
- Heavy bleeding or collapse
Practical preparation for your visit
Tap for details
Bring endoscopy or operative reports, pathology, imaging discs, medication lists, and a short written list of priorities. Ask how this step changes if molecular results, MRI, or second-look findings differ from the preliminary plan.
Shared decisions and realistic expectations
Tap for details
Educational pages cannot replace examination. Two patients with the same molecular testing in gastric cancer label may leave with different plans after staging. Ask what success looks like at three months and one year, and what the rescue plan is if the first pathway fails.
Somatic vs germline
Tap for details · key note inside
Tumor-only findings are not automatically hereditary. Germline counseling uses separate consent and cascade-testing rules. In the context of molecular testing in cancer, discuss how this point changes timing, alternatives, and follow-up with your surgical team before locking a plan.
Important
Tap for details · key note inside
Educational information only — not a substitute for clinical evaluation or personalized advice.

Frequently asked questions

Which markers matter most in advanced gastric cancer?
Tap for details
HER2, PD-L1 (CPS), CLDN18.2, and MSI/MMR commonly shape therapy discussions.
Is MSI only for metastatic disease?
Tap for details
MSI/MMR can influence care earlier in selected pathways; ask how it affects your stage.
Why does tissue stewardship matter?
Tap for details
Priority IHC/ISH/NGS can exhaust small samples — coordinate biopsies intentionally.
Can markers change over time?
Tap for details
Sometimes re-biopsy is considered if treatment decisions depend on updated status.

More chapters in this hub

Appointment / info

+90 542 725 50 70 WhatsApp Tumor board Back to hub →Full Turkish chapter →

Educational information only; not a substitute for clinical evaluation.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.